EsoBiotec’s core ENaBL (Engineered NanoBody Lentiviral) platform leverages targeted lentiviral vectors to deliver gene payload into endogenous patient immune cells inside the body. After in-vivo genetic reprogramming, modified T cells can specifically eliminate malignant tumor cells or aberrant autoreactive immune cells for oncology and autoimmune disease treatment.
Distinct from conventional ex vivo CAR-T workflows requiring leukapheresis and lymphodepletion chemotherapy, this in vivo platform only needs brief intravenous infusion. It drastically simplifies production workflows, shortens manufacturing cycles and improves patient accessibility to cell therapy products.
As a key supplier of anti-idiotype detection reagents and in vivo CAR monitoring solutions, CytoArt keeps close track of cutting-edge in vivo cell therapy industrial progress and supports global preclinical & FIH IIT projects with customized testing services.